April 7, 2026

Rapid Novor Inc., developer of EasyM®, a blood-based test for minimal residual disease (MRD) in multiple myeloma, has completed enrollment of 70 patients in a Canadian prospective study assessing the test’s clinical utility in newly diagnosed multiple myeloma (NDMM). Conducted in collaboration with Princess Margaret Cancer Centre (PMCC) and funded by a leading pharmaceutical partner, this study represents the first prospective Canadian study evaluating EasyM® for non-invasive MRD monitoring.

EasyM® detects monoclonal protein (M-protein) directly from peripheral blood, providing a highly sensitive, patient-friendly alternative to conventional bone marrow-based MRD testing. By reducing the need for invasive procedures and addressing limitations of traditional methods, EasyM® aims to improve treatment response assessment and enable earlier detection of relapse, supporting the shift toward MRD-guided therapy.

Rapid Novor remains dedicated to advancing human health through innovation in mass spectrometry-based proteomics and by developing technologies that decode immunity.

Like this article? Get more.

Sign up for our emails

Learn about upcoming webinars, new articles and occasional promotions. Emails come every few weeks on average.

Follow us on LinkedIn

Add some relevant articles to your feed, plus a little science fun.

Talk to Our Scientists.

We Have Sequenced 10,000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.